CaMKK2 as an emerging treatment target for bipolar disorder
Journal article
Kaiser, Jacqueline, Nay, Kevin, Horne, Christopher R., McAloon, Luke, Fuller, Oliver K., Muller, Abbey G., Whyte, Douglas G., Means, Anthony R., Walder, Ken, Berk, Michael, Hannan, Anthony J., Murphy, James M., Febbraio, Mark A., Gundlach, Andrew L. and Scott, John W.. (2023). CaMKK2 as an emerging treatment target for bipolar disorder. Molecular Psychiatry. pp. 1-12. https://doi.org/10.1038/s41380-023-02260-3
Authors | Kaiser, Jacqueline, Nay, Kevin, Horne, Christopher R., McAloon, Luke, Fuller, Oliver K., Muller, Abbey G., Whyte, Douglas G., Means, Anthony R., Walder, Ken, Berk, Michael, Hannan, Anthony J., Murphy, James M., Febbraio, Mark A., Gundlach, Andrew L. and Scott, John W. |
---|---|
Abstract | Current pharmacological treatments for bipolar disorder are inadequate and based on serendipitously discovered drugs often with limited efficacy, burdensome side-effects, and unclear mechanisms of action. Advances in drug development for the treatment of bipolar disorder remain incremental and have come largely from repurposing drugs used for other psychiatric conditions, a strategy that has failed to find truly revolutionary therapies, as it does not target the mood instability that characterises the condition. The lack of therapeutic innovation in the bipolar disorder field is largely due to a poor understanding of the underlying disease mechanisms and the consequent absence of validated drug targets. A compelling new treatment target is the Ca2+-calmodulin dependent protein kinase kinase-2 (CaMKK2) enzyme. CaMKK2 is highly enriched in brain neurons and regulates energy metabolism and neuronal processes that underpin higher order functions such as long-term memory, mood, and other affective functions. Loss-of-function polymorphisms and a rare missense mutation in human CAMKK2 are associated with bipolar disorder, and genetic deletion of Camkk2 in mice causes bipolar-like behaviours similar to those in patients. Furthermore, these behaviours are ameliorated by lithium, which increases CaMKK2 activity. In this review, we discuss multiple convergent lines of evidence that support targeting of CaMKK2 as a new treatment strategy for bipolar disorder. |
Year | 2023 |
Journal | Molecular Psychiatry |
Journal citation | pp. 1-12 |
Publisher | Springer Nature |
ISSN | 1476-5578 |
Digital Object Identifier (DOI) | https://doi.org/10.1038/s41380-023-02260-3 |
PubMed ID | 37730845 |
Scopus EID | 2-s2.0-85171543261 |
Open access | Published as ‘gold’ (paid) open access |
Page range | 1-12 |
Funder | National Health and Medical Research Council (NHMRC) |
Australian Catholic University (ACU) | |
Operational Infrastructure Support (OIS) Program, Victorian Government | |
Publisher's version | License File Access Level Open |
Output status | Published |
Publication dates | |
Online | 20 Sep 2023 |
Publication process dates | |
Accepted | 08 Sep 2023 |
Deposited | 09 Oct 2023 |
Grant ID | 2001817 |
1156072 | |
2017131 | |
1116936 | |
1194141 | |
1172929 | |
9000719 |
https://acuresearchbank.acu.edu.au/item/8zv3z/camkk2-as-an-emerging-treatment-target-for-bipolar-disorder
Download files
Publisher's version
OA_Kaiser_2023_CaMKK2_as_an_emerging_treatment_target.pdf | |
License: CC BY 4.0 | |
File access level: Open |
63
total views37
total downloads1
views this month0
downloads this month